🇺🇸 FDA
Patent

US 6369033

Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

expired A61KA61K38/00A61P

Quick answer

US patent 6369033 (Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein) held by Neurocrine Biosciences, Inc. expires Mon Apr 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Neurocrine Biosciences, Inc.
Grant date
Tue Apr 09 2002 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/00, A61P, A61P25/00, A61P25/28